Anders Bylock

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

Lars Wallentin, Robert G. Wilcox, W Douglas Weaver et al. · The Lancet · 2003 · 369 citations

Thrombosis, Oral Ximelagatran, Secondary Prophylaxis +11

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

Bengt I. Eriksson, Peter Kälebo, David Bergqvisty et al. · The Lancet · 2002 · 248 citations

Thrombosis, Venous Disease, Venous Thrombosis +9

Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: A prospective observational study

Lisa Ternström, Vladimir Radulovic, Martin Karlsson et al. · Thrombosis Research · 2010 · 124 citations

Cardiac Surgery, Thrombosis, Cardiovascular Disease +12

Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran

Giancarlo Agnelli, Bengt I. Eriksson, Alexander T. Cohen et al. · Thrombosis Research · 2008 · 94 citations

Thrombosis, Medicine, Anticoagulant +7

Ultrastructural studies on the localization of IgG in the aortic endothelium and subendothelial intima of atherosclerotic and nonatherosclerotic rabbits

Göran K. Hansson, Göran Bondjers, Anders Bylock et al. · Experimental and Molecular Pathology · 1980 · 85 citations

Vascular Disease, Subendothelial Intima, Vascular Adaptation +10